View:
United States securities and exchange commission logo
January 7, 2022
Paul Berns
Chief Executive Officer
Neumora Therapeutics, Inc.
65 Grove Street
Watertown, Massachusetts 02472
Re: Neumora
Therapeutics, Inc.
Amendment No. 1 to
Draft Registration
Statement on Form S-1
Submitted December
23, 2021
CIK No. 0001885522
Dear Mr. Berns:
We have reviewed your amended draft registration statement and
have the following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.
Please respond to this letter by providing the requested
information and either submitting
an amended draft registration statement or publicly filing your
registration statement on
EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
believe an amendment is appropriate, please tell us why in your
response.
After reviewing the information you provide in response to these
comments and your
amended draft registration statement or filed registration statement, we
may have additional
comments.
Amendment No. 1 to Draft Registration Statement on Form S-1 submitted
December 23, 2021
NMRA-511, page 138
1. We note your response
to our prior comment 9. Please revise your disclosure on page 138
to clarify, if true,
that the preclinical and Phase 1a trials for your NMRA-511 candidate
were also not powered
for statistical significance.
Paul Berns
FirstName LastNamePaul Berns
Neumora Therapeutics, Inc.
Comapany
January NameNeumora Therapeutics, Inc.
7, 2022
January
Page 2 7, 2022 Page 2
FirstName LastName
Exhibits
2. We note your disclosure in the footnotes to the exhibit index that
certain portions of
Exhibits 10.5(a), 10.5(b), 10.5(c), 10.6(a) and 10.6(b) have been
redacted. Pursuant to
Item 601(b)(10)(iv), please include a statement at the top of the
first page of each exhibit
stating that certain information has been excluded because it is both
not material and the
type of information that the registrant treats as private or
confidential.
You may contact Eric Atallah at 202-551-3663 or Al Pavot at 202-551-3738
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Jane Park at 202-551-7439 or Laura Crotty at 202-551-7614 with any other
questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Phillip Stoup, Esq.